170 related articles for article (PubMed ID: 36421832)
21. Liquid biopsy approaches for pleural effusion in lung cancer patients.
Baburaj G; Damerla RR; Udupa KS; Parida P; Munisamy M; Kolesar J; Rao M
Mol Biol Rep; 2020 Oct; 47(10):8179-8187. PubMed ID: 33029702
[TBL] [Abstract][Full Text] [Related]
22. Identification of suitable reference genes for the relative quantification of microRNAs in pleural effusion.
Han HS; Jo YN; Lee JY; Choi SY; Jeong Y; Yun J; Lee OJ
Oncol Lett; 2014 Oct; 8(4):1889-1895. PubMed ID: 25202432
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions.
Park DS; Kim D; Hwang KE; Hwang YR; Park C; Seol CH; Cho KH; Kim BR; Park SH; Jeong ET; Kim HR
Yonsei Med J; 2013 Mar; 54(2):396-402. PubMed ID: 23364973
[TBL] [Abstract][Full Text] [Related]
24. Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis.
Jotatsu T; Izumi H; Morimoto Y; Yatera K
Oncol Rep; 2020 Nov; 44(5):2198-2210. PubMed ID: 33000251
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of miR-4772-3p promotes enhanced regulatory T cell capacity in malignant pleural effusion by elevating Helios levels.
Yu WQ; Ji NF; Gu CJ; Sun ZX; Wang ZX; Chen ZQ; Ma Y; Wu ZZ; Wang YL; Wu CJ; Ding MD; Dai GH; Yao J; Jin RR; Huang M; Zhang MS
Chin Med J (Engl); 2019 Nov; 132(22):2705-2715. PubMed ID: 31725455
[TBL] [Abstract][Full Text] [Related]
26. Homocysteine: new tumor marker in pleural fluid.
Santotoribio JD; Cañavate-Solano C; Garcia-de la Torre A; Del Valle-Vazquez L; Arce-Matute F; Cuadros-Muñoz JF; Sanchez del Pino MJ; Bandez-Ruiz MJ; Piñuela-Rojas C; Perez-Ramos S
Tumour Biol; 2015 Sep; 36(10):7941-5. PubMed ID: 25956279
[TBL] [Abstract][Full Text] [Related]
27. Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer.
Biaoxue R; Min L; Tian F; Wenlong G; Hua L
BMC Pulm Med; 2018 Dec; 18(1):188. PubMed ID: 30522463
[TBL] [Abstract][Full Text] [Related]
28. mRNA markers associated with malignant pleural effusion.
Hsu SC; Chang SY; Hwang YT; Terng HJ; Tsai CL; Shen CH; Huang SK; Chian CF
Sci Rep; 2023 Apr; 13(1):6677. PubMed ID: 37095178
[TBL] [Abstract][Full Text] [Related]
29. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion.
Chierakul N; Kanitsap A; Chaiprasert A; Viriyataveekul R
Respirology; 2004 Mar; 9(1):66-9. PubMed ID: 14982604
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
31. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion.
Görgün D; Seçik F; Midilli K; Akkaya V; Yıldız P
Respir Med; 2013 Aug; 107(8):1260-5. PubMed ID: 23791464
[TBL] [Abstract][Full Text] [Related]
32. Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a.
Barone I; Gelsomino L; Accattatis FM; Giordano F; Gyorffy B; Panza S; Giuliano M; Veneziani BM; Arpino G; De Angelis C; De Placido P; Bonofiglio D; Andò S; Giordano C; Catalano S
J Transl Med; 2023 Mar; 21(1):232. PubMed ID: 37004031
[TBL] [Abstract][Full Text] [Related]
33. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
Botana-Rial M; Casado-Rey P; Leiro-Fernández V; Andrade-Olivié M; Represas-Represas C; Fernández-Villar A
Clin Lab; 2011; 57(5-6):373-8. PubMed ID: 21755828
[TBL] [Abstract][Full Text] [Related]
34. Combined Methylation of
Zhong Q; Wang Y; Liang C; Wei F; She B
Discov Med; 2023 Oct; 35(178):845-852. PubMed ID: 37811622
[TBL] [Abstract][Full Text] [Related]
35. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H; Ko Y; Lee CY
BMC Cancer; 2020 Aug; 20(1):825. PubMed ID: 32867726
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
37. S100A2: A potential biomarker to differentiate malignant from tuberculous pleural effusion.
Wang T; Wang N; Zhang L; Liu Y; Thakur A
Indian J Cancer; 2021; 58(2):241-247. PubMed ID: 33402562
[TBL] [Abstract][Full Text] [Related]
38. Metabolic and lipidomic characterization of malignant pleural effusion in human lung cancer.
Yang Z; Song Z; Chen Z; Guo Z; Jin H; Ding C; Hong Y; Cai Z
J Pharm Biomed Anal; 2020 Feb; 180():113069. PubMed ID: 31884394
[TBL] [Abstract][Full Text] [Related]
39. Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis.
Zhu J; Feng M; Liang L; Zeng N; Wan C; Yang T; Shen Y; Wen F
BMC Cancer; 2017 Aug; 17(1):590. PubMed ID: 28854885
[TBL] [Abstract][Full Text] [Related]
40. The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion.
Huang L
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6759-6766. PubMed ID: 32633367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
